Post-transplant malignancy: Focusing on virus-associated etiologies, pathogenesis, evidence-based management algorithms, present status of adoptive immunotherapy and future directions

Table 1 Post-transplant cancers standardized incidence ratio compared to general population[12]

Standardized incidence ratio compared to general population	Post-transplant cancers
> 5	NMSC, PTLD, lip, RCC and KS
2-5	Melanoma, thyroid cancer, leukemia and multiple myeloma
< 2	Breast, brain, lung and prostate cancer

NMSC: Non-melanomatous skin cancers; PTLD: Post-transplant lymphoproliferative disorders; RCC: Renal cell carcinoma; KS: Kaposi’s sarcoma.